NEW YORK, Aug. 22, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced results for the quarter ended June 30, 2017, and provided an overview of recent operational highlights. “The development of cannabinoid-based therapeutics continues to gather momentum in the U.S. and around the […]
Visit the Maricann Group Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
TORONTO, ONTARIO–(Marketwired – Aug. 22, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that Dr. Arun Sanyal, M.D., will join the Company as a Scientific Advisor for cannabinoid-based therapeutics targeting liver diseases. […]
As a whole, marijuana stocks are on fire. Through about mid-July, the average marijuana stock was up over 300% on a trailing-12-month basis, albeit one stock with a 2,363% gain at the time had skewed the results. Even if this outlier were removed from the equation, the largest roughly one dozen weed stocks had jumped by […]
Two area residents were charged with class D drug felonies and misdemeanors during two separate traffic stops conducted on Monday, Aug. 14, and Wednesday, Aug. 16. According to a probable cause statement, a Marshall Police Department officer observed a passenger vehicle traveling north on Odell Avenue near Vest Street to have only one operating headlamp. […]
Two separate traffic stops, conducted on Interstate 70, resulted in drug charges filed against three individuals on Friday, Aug. 11. According to a probable cause statement, on March 3, at approximately 9:45 p.m., a Missouri State Highway Patrol trooper conducted a traffic stop at the 79.8-mile marker on a silver Jeep SUV for following another […]
Cannabis testing allows consumers to make informed purchasing decisions based on the strength and composition of cannabis products. Accurate testing is crucial for medical cannabis patients who need specific therapeutic effects. It’s also important for adult-use consumers because products vary widely in their potency, which will influence the experience. There is a variety of cannabis […]
By Marie Powers,News Editor The legal, regulatory and marketing hurdles faced by companies with commercial cannabinoids have not deterred new entrants seeking to build better mousetraps. Although many companies in the field continue to rely on the cannabis plant as the starting point for their RD efforts, some have turned to what they consider next-generation […]
August 18, 2017 (Investorideas.com Newswire) Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks releases a video/ interview featuring David Schrader, Chief Operating Officer of Scythian Biosciences (TSX.V: SCYB), a company developing a drug regimen for concussion and traumatic brain injury using a cannabinoid-based combination drug therapy. Watch video: https://www.youtube.com/watch?v=DaNLaGh0G-w Scythian […]
…read more at https://www.newcannabisventures.com/cannabinoid-derivatives-developer-scientus-pharma-lands-11-5-million-investment-from-aphria/
What’s in a name? When it comes to marijuana strains, results vary — sometimes spectacularly. And according to a story in Marijuana Business Daily, the marijuana industry has about had its fill of it. There are thousands of marijuana strain names. Each one is supposed to refer to a specific type of pot, but frequently […]
Canadian company, Aphria, has announced a $11.5 million strategic investment into biopharmaceutical company, Scientus Pharma, which focuses on the development of drugs that target the endocannabinoid receptors to treat diseases. × Under the terms of the investment agreement, over two years an interest of 8% will be paid semi-annually,…read more at http://www.epmmagazine.com/news/aphria-announces-strategic-investment-in-cannabinoid-company/
Zynerba Pharmaceuticals announces that results from Phase 2 STOP trial support continued development of ZYN002 in osteoarthritis. Zynerba Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid treatments, today reported top line results from its Phase 2 STOP (Synthetic Transdermal Cannabidiol for Treatment of Knee Pain due to Osteoarthritis) clinical […]
Zynerba Pharmaceuticals announces that results from Phase 2 STOP trial support continued development of ZYN002 in osteoarthritis. Zynerba Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid treatments, today reported top line results from its Phase 2 STOP (Synthetic Transdermal Cannabidiol for Treatment of Knee Pain due to Osteoarthritis) clinical […]
Coming from a few years of playing contact sports…concussions are no laughing matter. In particular receiving them back to back. I find the research being done at the University of Miami, in regards to studying the brain of past pro athletes in both the NFL and in boxing, absolutely fascinating. …read more at https://investorintel.com/sectors/agribusiness-mmj/agbusiness-mmj-intel/scythian-treat-secondary-effects-traumatic-brain-injuries-cannabinoids/